(Des-Thr7)-Glucagon, CAS: 1802078-28-9

(Des Thr7) Glucagon is a modified glucagon analog missing the threonine residue at position 7, a site in the N-terminal region important for the glucagon receptor (GCGR) interaction. Retaining measurable bioactivity in peptide screenings, it is a valuable tool in diabetes research for studying subtle structural changes and protein interactions related to glucagon and GCGR.

For research use only, do not use in humans!

Produced by JPT Peptide Technologies, a leader in custom peptide synthesis and diabetes reagents.

(Des-Thr7)-Glucagon, CAS: 1802078-28-9 - Specifications

• Peptide sequence: H-HSQGTFSDYSKYLDSRRAQDFVQWLMNT-OH
• Amount: 0.5 mg net (50 x 10 µg) (AAA)
• Purity: >95% (HPLC-MS)
• Counterion: TFA
• Delivery Format: Freeze-dried in plastic vial
• Chemical formula: C149H218N42O47S
• MW (average): 3381.69
• Application(s): Diabetes research
• Condition(s)/Topic(s): Diabetes
• Standard Delivery Time: 2-5 days
• CAS: 1802078-28-9
• SMILES: N[C@@H](CC1=CNC=N1)C(N[C@@H](CO)C(N[C@@H](CCC(N)=O)C(NCC(N[C@@H]([C@@H](C)O)C(N[C@@H](CC2=CC=CC=C2)C(N[C@H](C(N[C@@H](CC(O)=O)C(N[C@@H](CC3=CC=C(O)C=C3)C(N[C@@H](CO)C(N[C@H](C(N[C@@H](CC4=CC=C(O)C=C4)C(N[C@@H](CC(C)C)C(N[C@@H](CC(O)=O)C(N[C@@H](CO)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](C)C(N[C@@H](CCC(N)=O)C(N[C@@H](CC(O)=O)C(N[C@@H](CC5=CC=CC=C5)C(N[C@@H](C(C)C)C(N[C@@H](CCC(N)=O)C(N[C@@H](CC6=CNC7=C6C=CC=C7)C(N[C@@H](CC(C)C)C(N[C@@H](CCSC)C(N[C@@H](CC(N)=O)C(N[C@@H]([C@H](O)C)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)CCCCN)=O)=O)=O)=O)CO)=O)=O)=O)=O)=O)=O

Why Use DES-THR7-Glucagon Along with Native Glucagon?

Native glucagon is a pancreatic 29-amino-acid peptide hormone that maintains glucose homeostasis by opposing insulin. In response to low blood sugar, it activates the glucagon receptor (GCGR), stimulating hepatic glycogenolysis and gluconeogenesis to raise glucose levels. Primarily used as an emergency treatment for severe hypoglycemia, glucagon’s therapeutic potential in diabetes is also being investigated.

However, studying native glucagon alone is insufficient to fully understand glucagon-GCGR interactions. Experiments with analogs structurally modified at the receptor interaction site, such as DES-THR7-Glucagon, may offer deeper insights into GCGR binding, signaling, and function.

Retaining measurable bioactivity in peptide screenings, Des Thr7 Glucagon can be ideal for mapping binding interactions and analyzing structure-function relationships that native glucagon alone cannot support.

We also offer unmodified Glucagon!

Research Areas/Applications for Glucagon (Des-Thr7), Human, CAS: 1802078-28-9

• Diabetes and hypoglycemia research: Researched for its role in glucagon receptor signaling and glucose regulation, supporting studies on insulin response and counter-regulatory mechanisms during hypoglycemia.
• Obesity and weight loss research: Studied in metabolic research examining energy expenditure, lipid metabolism, and appetite control influenced by glucagon analogs and GCGR activity.
• Protein interaction assays: Explored in binding studies assessing glucagon-receptor interactions, ligand affinity, and signal transduction efficiency.
• Energy and glucose metabolism studies: Researched in biochemical and cell-based models analyzing hepatic glucose output, energy utilization, and overall metabolic balance.
• Hormonal and metabolic disorder studies: Studied in models of endocrine dysfunction and metabolic syndrome to investigate altered glucagon and GLP-1 signaling.
• Peptide screenings by immunoassay: Explored in ELISA and related immunoassay formats to detect glucagon analogs and assess receptor binding or assay specificity.
• Receptor binding and GCGR signaling: Researched to characterize GCGR activation, downstream signaling, and associated metabolic effects.
• Structure-function relationship studies: Studied to understand how the Thr7 deletion affects peptide structure, stability, and biological activity.
• Drug development targeting the glucagon receptor: Explored for designing and optimizing GCGR-based therapeutics for metabolic and endocrine disorders.

Key Benefits of (Des Thr7) Glucagon, CAS: 1802078-28-9

• Improved stability: The deletion of Thr7 enhances peptide stability under physiological conditions.
• Altered receptor interaction: Modifies glucagon receptor binding dynamics, enabling detailed GCGR signaling studies.
• Valuable for structure-activity relationship analysis: Facilitates investigations by comparing with native glucagon.
• Model for peptide design: Serves as a reference analog for developing and optimizing glucagon-based therapeutics.

Key Concepts

Structural and Functional Features of (Des Thr7) Glucagon

Glucagon (Des-Thr7) is a modified analog of human glucagon in which the threonine residue at position 7 is deleted. This deletion removes a hydrogen-bonding site within an aggregation-prone region of the peptide, improving conformational stability and reducing amyloid fibril formation.

Since Thr7 is not directly involved in receptor recognition or activation, the modification preserves the peptide’s biological activity while enhancing its structural resilience. As a result, (Des-Thr7)-Glucagon serves as a valuable analog for studying structure-function relationships and for designing more stable glucagon-based therapeutics.

JPT’s Glucagon Peptides

Glucagon is a 29-amino acid polypeptide. Its primary sequence in humans is: NH2-His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Arg-Arg-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr-COOH. Glucagon is a non-steroid peptide hormone produced in the pancreas. Its effect is opposite to that of insulin. Glucagon and insulin regulating blood glucose homeostasis making glucagon a potential target for the therapeutic treatment of diabetes. JPT Peptide Technologies has substantial, long-standing expertise in providing peptides in all formats, scales and modifications to the global scientific community. All our catalog peptides are provided with HPLC-MS analyses to confirm the identity and demonstrate the high quality of our peptides.

• All peptides are made in Germany
• Bulk orders or custom peptide synthesis upon request
• Provision of freeze-dried aliquots for enhanced stability
• Proven track record
• Need the conjugated or modified peptide? Contact us!